About
Marc Rivière joined the Montreal-based TVM Capital Life Science team in 2013 after twenty years of international drug development preceded by ten years of medical and public health practice in Europe and the Middle East. An experienced executive with a track record in successfully building and managing clinical programs, Marc’s expertise encompasses all aspects of drug development in different clinical indications from pre-clinical development to post marketing surveillance. At TVM Capital Life Science, he focuses on evaluation of deal opportunities and investment management for therapeutics. He also works closely with the firm’s strategic partner Eli Lilly & Co. and its drug development division Chorus. He also serves on the board of publicly listed (Euronext) Cerenis Therapeutics, Toulouse, France, Ann Arbor, USA. Prior to joining TVM Capital Life Science, Marc was Vice-President, Axcan Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance and a membe
Position in the VCSift Database
- • 11 investors at TVM Capital are tracked.
- • 626 investors hold the General Partner role in VCSift. Marc Riviere is one of them.
- • 686 investors are based in Montréal, Quebec, Canada.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Montréal, Canada
Contact Information
Find more investors like Marc
Search Investors